p53 level and MGMT promoter methylation are playing a role in Zika
virus replication in glioblastoma
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Introduction

Glioblastoma (GBM) is a malignant primary brain cancer. It
is a devastating cancer not only because of its poor
prognosis, but also because it robs patients of their
strength, memory, personality, and language. The poor
median survival rate for patients with GBM of 15 months
has not budged for the past 15 years, when the current
standard treatment was first approved. There is no standard
of care chemotherapy for recurrent GBM. Needless to say,
novel treatments and treatment strategies for GBM are
needed. One such novel treatment strategy is an oncolytic
virus. Zika virus (ZIKV) affinity for fetal neural stem cells has
made it a compelling candidate as an oncolytic therapy for
glioblastoma. Previous studies have shown that ZIKV does
infect and replicate in most but not all GBM cancer cells.
Understanding the genetic milieu that is permissive for ZIKV
infection is critical to the creation of a safe and effective viral
oncolytic treatment. This report presents initial data for a
ZIKV replication gene signature.
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Fig 2. Effect of MGMT overexpression and MGMTKO in ZIKV
replication. (A) Relative expression level of AXL, MGMT and
p53 in GMB cell lines. (B and C) MGMT overexpression and
comparative ZIKV infection in GBM cell lines. (D and E)
Expression of MGMT and ZIKV infection in MGMTKO MCF7
cell lines.
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Objective
The purpose of this study is to understand the role of p53
level and MGMT promoter methylation in ZIKV replication in
glioblastoma cancer cells.

Methods
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ZIKV strain MR766 was propagated in Vero cells. Viral
stock was titrated by plaque assays. Western blot was used
to characterize MGMT, AXL and p53 expression in eight
commercial GBM cell lines (LN229, U87, A172, U251,
LN18, T98G, U137, and U118). We have also used seven
patient derived glioblastoma caner stem cells to validate the
hypothesis. The cell lines were stratified by MGMT
promoter methylation status and were exposed to ZIKV at
MOI 1. The percentage of infected cells was quantified by
flow cytometry using the pan-flavivirus anti-E protein Ab
4G2.

Results
ZIKV does not replicate in unmethylated-MGMT and
elevated p53 expression glioblastoma cell lines.

Fig 3. ZIKV infection and replication in MGMT-positive
and p53 positive patient derived glioblastoma cell lines. Cell
were challenged with ZIKV MOI 1 for 24, 48, and 72 hour
post infection, the percentage of infected cells were
quantified by flow cytometry using 4G2 antibody.

Conclusion
Based on these results, there is a clear difference in the
ability of ZIKV to replicate in GBM cell lines based on
MGMT and p53 expression. Additional work is underway
to understand the mechanism(s) underlying these findings
and to define a ZIKV replication gene signature.
Fig 1. ZIKV infection and replication. (A and B) The human
glioblastoma cell lines were challenged with ZIKV MOI 1 for
24, 48, and 72 hour post infection, the percentage of infected
cells were quantified by flow cytometry using 4G2 antibody.

Future directions
 RNA-seq analysis of ZIKV replicating and non-replicating
GBM cell lines to find differentially expressed genes.
 Validation of differentially expressed genes in ZIKV
replication.
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